Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

ConditionsBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Metastatic Ovarian Cancer Cervical Carcinoma Endometrial Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Eligibility criteria

Qualifiers

Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic;

Patients who have received treatment for breast cancer or gynecologic cancer since January 2010;

Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data.

Disqualifiers

no exclusion criteria

Trial design

Treatments tested in this trial

Oncologic drugs administered for treatment of breast cancer
Oncologic drug administered for treatment of gynecologic cancer

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

Source ClinicalTrials.gov